Orig3n, a Boston-based biotech company, today announced a research collaboration agreement with Harvard University, led by a faculty member from the Harvard Stem Cell Institute (HSCI), to develop cell therapies for the treatment of cardiovascular disease.
October 2, 2018
· 2 min read